Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas

被引：107

作者：

Feldman, A. L. ^{[1
]}

Sun, D. X. ^{[1
]}

Law, M. E. ^{[1
]}

Novak, A. J. ^{[2
]}

Attygalle, A. D. ^{[3
]}

Thorland, E. C. ^{[1
]}

Fink, S. R. ^{[1
]}

Vrana, J. A. ^{[1
]}

Caron, B. L. ^{[1
]}

Morice, W. G. ^{[1
]}

Remstein, E. D. ^{[1
]}

Grogg, K. L. ^{[1
]}

Kurtin, P. J. ^{[1
]}

Macon, W. R. ^{[1
]}

Dogan, A. ^{[1
]}

机构：

[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Hematol, Rochester, MN 55905 USA

[3] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England

来源：

LEUKEMIA | 2008年 / 22卷 / 06期

关键词：

peripheral T-cell lymphoma; Syk; tyrosine kinase; phosphorylation;

D O I：

10.1038/leu.2008.77

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression of Syk PTK in 141 PTCLs. Syk was positive by immunohistochemistry (IHC) in 133 PTCLs (94%), whereas normal T cells were negative. Western blot on frozen tissue (n = 6) and flow cytometry on cell suspensions (n = 4) correlated with IHC results in paraffin. Additionally, western blot demonstrated that Syk-positive PTCLs show tyrosine (525/526) phosphorylation, known to be required for Syk activation. Fluorescence in situ hybridization showed no SYK/ITK translocation in 86 cases. Overexpression of Syk, phosphorylation of its Y525/526 residues and the availability of orally available Syk inhibitors suggest that Syk merits further evaluation as a candidate target for pharmacologic PTK inhibition in patients with PTCL.

引用

页码：1139 / 1143

页数：5

共 50 条

[41] Novel Therapies in Peripheral T-Cell Lymphomas
O'Leary, Hilary M.
Savage, Kerry J.
CURRENT ONCOLOGY REPORTS, 2008, 10 (05) : 404 - 411
[42] THE PROGNOSTIC FACTORS FOR PERIPHERAL T-CELL LYMPHOMAS
LIANG, R
LOKE, SL
CHAN, ACL
HEMATOLOGICAL ONCOLOGY, 1992, 10 (3-4) : 135 - 140
[43] BELINOSTAT FOR THE TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS
McDermott, J.
Jimeno, A.
DRUGS OF TODAY, 2014, 50 (05) : 337 - 345
[44] INTENSIVE CHEMOTHERAPY FOR PERIPHERAL T-CELL LYMPHOMAS
LIANG, R
TODD, D
CHAN, TK
CHIU, E
LIE, A
HO, FCS
LOKE, SL
HEMATOLOGICAL ONCOLOGY, 1992, 10 (3-4) : 155 - 161
[45] Peripheral T-Cell Lymphomas: Therapeutic Approaches
Sibon, David
CANCERS, 2022, 14 (09)
[46] Targeting Aurora kinase in peripheral T-cell non-Hodgkin's lymphomas
Mahadevan, Daruka
Qi, Wenqing
Liu, Xiaobing
Cooke, Laurence S.
Agarwal, Amit
Persky, Daniel O.
Miller, Thomas P.
CANCER RESEARCH, 2012, 72
[47] The Syk family of protein tyrosine kinases in T-cell activation and development
Chu, DH
Morita, CT
Weiss, A
IMMUNOLOGICAL REVIEWS, 1998, 165 : 167 - 180
[48] Hematopoietic stem cell transplantation in peripheral T-cell lymphomas
Paolo, Corradini
Lucia, Farina
Anna, Dodero
LEUKEMIA & LYMPHOMA, 2007, 48 (08) : 1496 - 1501
[49] Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations
Geissinger, E.
Bonzheim, I.
Krenacs, L.
Roth, S.
Reimer, P.
Wilhelm, M.
Mueller-Hermelink, H. K.
Ruediger, T.
JOURNAL OF PATHOLOGY, 2006, 210 (02): : 172 - 180
[50] PERIPHERAL T-CELL LYMPHOMAS - MORPHOLOGY, IMMUNHISTOCHEMISTRY, CYTOGENETICS
LENNERT, K
FELLER, AC
GODDESALZ, E
ONKOLOGIE, 1986, 9 (02): : 97 - &

← 1 2 3 4 5 →